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Objective. This experimental study exam-
ined the effect of erythropoietin (Epo) in 
a rat model and particularly in a hypoxia-
reoxygenation (HR) protocol. The effect of 
that molecule was studied biochemically 
using blood mean chloride (Cl) levels. 
Materials and methods. 40 rats of mean 
weight 247.7 g were used in the study. Cl 
levels were measured at 60 min (groups A 
and C) and at 120 min (groups B and D) of 
reoxygenation. Erythropoietin was admin-
istered only in groups C and D.
Results. Epo administration non-signifi-
cantly decreased Cl levels by 1.07%+0.91% 
(p=0.2635). Reoxygenation time non-
significantly decreased Cl levels by 
0.68%+0.92% (P= 0.4457). However, eryth-
ropoietin administration and reoxygena-
tion time together produced a non-signifi-
cant combined effect in decreasing Cl levels 
by 0.74%+0.54% (P= 0.1701).
Conclusions. Epo administration, reoxy-
genation time and their interaction have 
non-significant, short-term, decreasing ef-
fects on Cl levels.  
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INTRODUCTION
Erythropoietin (Epo) is generally one of 
the more well studied growth factors. Epo 
is implicated in over 29,194 known bio-
medical studies at present. At least 10.39% 
of these studies concern tissue hypoxia 
and reoxygenation (HR) experiments. Im-
portant progress has been made concern-
ing Epo usage in reversing HR injuries of 
adjacent organs and certainly patients’ 
health. Satisfactory answers to basic ques-
tions have not yet been provided, such 
as its action velocity, the administration 
timing and the dosage. The concept is the 
knowledge promotion away from the origi-
nal action of Epo as a glycoprotein cytokine 
secreted by the kidney in response to cellu-
lar hypoxia; which stimulates red blood cell 
production (erythropoiesis) in the bone 
marrow. However, just a few related reports 
were found, not completely covering more 
specific matters. A numeric evaluation of 
Epo efficacy was yielded by a meta-analysis 
of 34 published studies, based on the same 
experimental setting, using the same end-
points (table 1). 
The aim of this experimental study was to 
examine the effect of Epo on a rat model 
and particularly in an HR protocol. The ef-
fects of that model were studied by measur-
ing the blood mean chloride (Cl) levels. 
MATERIALS AND METHODS
Animal preparation
The prefectural vet of East Attiki licensed 
this experiment under 3693/12-11-2010 
& 14/10-1-2012 decisions. All substances, 
equipment and consumables needed for the 
study were donated as a courtesy of ELPEN 
Pharmaceuticals Co Inc. S.A. at Pikermi, 
Attiki. Appropriate care was adopted for 
female albino Wistar rats. Seven days pre-
experimental normal housing in labora-
tory included ad libitum diet. Prenarcosis 
preceded of non-stop intra-experimental 
general anesthesia, (1) electrocardiogram, 
acidometry and oxygen supply. Post-exper-
imental euthanasia did not permit preser-
vation of the rodents. 
The rodents were randomly delivered to 
four experimental groups, each one con-
sisted of 10 animals. The 4 groups had 
common the stage of preceded hypoxia of 
45 min induced by laparotomic clamping 
inferior aorta over renal arteries by forceps. 
Afterwards, the clamp removal restored re-
oxygenation by inferior aorta patency rees-
tablishment. Reoxygenation of 60 min was 
followed for group A. Reoxygenation of 120 
min was followed for group B. Immediate 
Epo intravenous (IV) administration and 
reoxygenation of 60 min was followed for 
group C. Immediate Epo IV administration 
and reoxygenation of 120 min was followed 
for group D. The dosage of molecule Epo 
was 10 mg/kg body mass per animal. Epo 
administration was performed at the time 
of reoxygenation, through inferior vena 
cava catheter. The Cl levels evaluations 
were performed at 60 min of reoxygena-
tion for A and C groups and at 120 min 
of reoxygenation for B and D groups. The 
mean mass of the forty (40) female Wistar 
albino rats used was 247.7 g [Standard De-
viation (SD): 34.99172 g], min weight 165 g 
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and max weight 320 g. Rats’ mass could be 
probably a confusing factor, e.g. the more 
obese rats to have higher Cl levels. This as-
sumption was also investigated.
Model of hypoxia-reoxygenation injury
Control groups
20 control rats of mean weight 252.5 g [SD: 
39.31988 g] experienced hypoxia for 45 
min followed by reoxygenation. 
Group A
Reoxygenation lasted 60 min concern-
ing 10 control rats of mean weight 243 g 
[SD: 45.77724 g] and mean Cl levels 103.4 
mmol/l [SD: 2.1187 mmol/l] (table 2).    
Group B
Reoxygenation lasted 120 min concern-
ing 10 control rats of mean weight 262 g 
[SD: 31.10913 g] and mean Cl levels 102.9 
mmol/l [SD: 1.911951 mmol/l] (table 2).  
Erythropoietin group
20 Epo rats of mean weight 242.9 g [SD: 
30.3105 g] experienced hypoxia for 45 min 
followed by reoxygenation in the begin-
ning of which 10 mg Epo /kg body weight 
were IV administered. 
Group C
Reoxygenation lasted 60 min concern-
ing 10 Epo rats of mean weight 242.8 g 
[SD: 29.33636 g] and mean Cl levels 102.5 
mmol/l [SD: 2.068279 mmol/l] (table 2).    
Group D
Reoxygenation lasted 120 min concern-
ing 10 Epo rats of mean weight 243 g 
[SD: 32.84644 g] and mean Cl levels 101.6 
mmol/l [SD: 4.695151 mmol/l] (table 2).  
Statistical analysis 
Every weight and Cl level group was com-
pared with each other from 3 remained 
groups applying respective statistical 
standard t-tests (table 3). If any probable 
significant difference among Cl levels was 
raised, it would be investigated whether 
owed in any respective probable significant 
mass one (table 3). Then, the application of 
generalized linear models (glm) was fol-
lowed. It included as dependant variable 
the Cl levels. The 3 independent variables 
were the Epo administration or no, the re-
oxygenation time and their interaction. In-
serting the rats’ mass as independent vari-
able at glm, a non significant correlation 
appeared with Cl levels (p=0.0577), so as 
to further investigation was not required. 
The statistical analysis was performed by 
Stata 6.0 software [Stata 6.0, StataCorp LP, 
Texas, USA].
RESULTS 
Epo administration non significantly 
decreased the Cl levels by 1.1 mmol/l 
[-2.944603 mmol/l - 0.7446032 mmol/l] 
(P=0.2348). This finding was in accord-
ance with the results of standard t-test 
(p=0.2922). Reoxygenation time non-
significantly decreased the Cl levels by 
0.7 mmol/l [-2.565532 mmol/l - 1.165532 
mmol/l] (P= 0.4522), in accordance also 
with standard t-test (P= 0.4392). However, 
erythropoietin administration and reoxy-
genation time together produced a non sig-
nificant combined effect in decreasing the 
Cl levels by 0.7636364 mmol/l [-1.869013 
mmol/l - 0.3417403 mmol/l] (P= 0.1701). 
Reviewing the above and table 3, the tables 
4 and 5 sum up concerning the decreasing 
influence of Epo in connection with reoxy-
genation time. 
Table 1. Erythropoietin (Epo) influence (+SD) on the levels of some serum (1) variables concerning reperfusion (rep) time                                                            
Variable 1h rep         p-value         1.5h rep         p-value         2h rep p-value        interaction of 
Epo and rep
p-value    
White BCC         +24.01%+13.38%  0.1012    +22.09%+9.11%     0.0163 +20.17%+12.94% 0.0902  +14.63%+5.40%  0.0080
Red BCC +1.45%+3.31% 0.6589 +0.37%+3.02% 0.9048 -0.70%+4.68% 0.8844 +0.81%+1.79% 0.6446
Hematocrit     +0.14%+2.89%      0.9626        -0.61%+2.37%      0.8072        -1.37%+4.05% 0.7485       +0.24%+1.38%       0.8586
Hemoglobin +4.09%+5.20%           0.3350 +2.15%+2.63              0.4527 +0.20%+5.08%           0.9584 +1.31%+1.59%           0.3984       
MCH +0.01%+1.29%  0.9904    +0.67%+0.80%  0.3549    +1.34%+1.08%  0.1509   -0.36%+0.47%   0.4430
MCV +0.01%±1.08% 0.9904 +0.56%±0.66% 0.3549 +1.12%±0.91% 0.1509 +0.30%±0.39% 0.4430
MCHC +1.82%+0.56% 0.0076 +1.73%+0.50% 0.0016 +1.65%+0.92% 0.0721 +0.89%+0.31% 0.0061
RbcDW -1.85%+4.24% 0.6703 -1.64%+2.53% 0.5159 -1.43%+3.34% 0.6078 -1.06%+1.43% 0.4733
Plt C -7.32%+13.11% 0.5219 -2.14%+8.04% 0.7581 +3.04%+10.78% 0.7204 -0.16%+4.76% 0.9725
MPV +3.82%+4.10% 0.3105 -0.12%+2.13% 0.9513 -4.07%+3.75% 0.2608 -0.27%+0.92% 0.7585
Platelet DW +1.60%+0.80%  0.0765     +1.36%+0.58%     0.0205 +1.13%+0.74% 0.1152   +0.37%+0.37%  0.0615
Platelet-crit -16.47%+10.40%   0.0921    -13.74%+7.01%      0.0158 -11.01%+7.34% 0.0882   -6.88%+3.69%   0.0615
Glucose (7) +0.75%+8.11% 0.9307 +5.59%+6.46% 0.3208 +10.44%+10.99% 0.3491 +4.94%+3.81% 0.1892
Urea +21.42%+7.84% 0.0115 +20.11%+7.25% 0.0059 +18.80%+9.44% 0.0709 +15.64%+4.04% 0.0003
Creatinine -0.10%+9.78% 0.9904 -4.84%+5.78% 0.3721 -9.59%+7.74% 0.1509 -2.62%+3.49% 0.4430
Uric acid                       +10.13%+15.10%   0.4917   +15.86%+10.21%   0.1408 +21.59%+15.45% 0.1940   +9.33%+6.16%  0.1264
Total protei               -0.02%+2.47%     0.9904    -1.27%+1.51%        0.3721      -2.52%+2.03% 0.1509     -0.68%+2.48%      0.4430
Albumins -4.61%+4.21% 0.2530 -9.28%+3.20% 0.0054 -13.96%+5.03% 0.0095 -5.37%+2.73% 0.0072
ALT +18.89%+12.42% 0.1372 +7.63%+18.94% 0.6396 -3.63%+25.19% 0.8617  +8.03%+11.36% 0.4698
AST +29.53%+9.72% 0.0096 +26.71%+13.17% 0.0235 +23.89%+21.59% 0.1709 +19.73%+7.70% 0.0119
γGT -19.35%+18.58% 0.2362 -12.70%+13.11% 0.3541 -6.06%+19.96% 0.7800 -4.62%+7.97% 0.5534
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ALP  +0.20%+18.57%    0.9904   +10.70%+12.78%   0.3549   +21.20%+17.11%   0.1509    +5.79%+7.72%    0.4430
ACP         +0.06%+5.79%    0.9904   +3.11%+3.71%        0.3172    +6.16%+4.97%    0.1509    +1.68%+2.23%      0.4430
CPK  +0.15%+14.09%    0.9904   +7.91%+9.44%        0.3549   +15.67%+12.65%   0.1509    +4.28%+5.70%     0.4430
CK-MB +0.08%+7.90% 0.9904 +4.28%+5.11% 0.3721 +8.49%+6.85% 0.1509 +2.32%+3.09% 0.4430
LDH  +0.08%+7.92%     0.9904    +4.48%+5.35%        0.3549     +8.89%+7.17%   0.1509    +2.42%+3.22%     0.4430
Sodium +0.72%+0.74%      0.3054   +0.21%+0.63%       0.7136   -0.29%+1.09% 0.7670    -0.11%+0.38%    0.7531
Potassium -6.17%+4.94% 0.1540 -2.21%+3.66% 0.5134 +1.74%+5.43% 0.7299 +0.18%+2.22% 0.9338
Calcium 0.28%+1.19% 0.8065 -0.56%+1.13% 0.5761 -1.41%+2.08% 0.4100 -0.34%+0.68% 0.6095
Phosphorus +1.92%+5.25% 0.6982 +3.95%+3.35% 0.2100 +5.98%+4.81% 0.2930 +2.45%+2.01% 0.2168
Magnesium +1%+6.20% 0.8596 -1.09%+3.34% 0.7248 -3.19%+3.90% 0.3729 -0.19%+1.93% 0.9197
Amylase +6.50%+9.15% 0.4161 +5.04%+6.12% 0.3831 +3.59%+8.42% 0.6649 +4.36%+3.65% 0.2258
Progesteron -0.20%+18.65%    0.9904   -8.86%+10.58%       0.3549   -17.53%+14.15%        0.1509    -4.79%+6.39%    0.4430
Testosteron (2) +47.05%+58.96% 0.4120  +71.21%+44.19% 0.1080       +95.38%+46.14% 0.0470 +27.65%+27.21% 0.3006
Μean   +3.52%+12.31% 0.5694   +4.60%+14.69% 0.3743 +5.69%+18.79% 0.3463 +2.93%+7.21% 0.4114
Table 2. Weight and chloride (Cl) mean levels and Std. dev. of groups 
Groups Variable Mean Std. Dev   
Α Weight 243 g 45.77724 g
Α Cl 103.4 mmol/l 2.1187 mmol/l
B Weight 262 g 31.10913 g
B Cl 102.9 mmol/l 1.911951 mmol/l
C Weight 242.8 g 29.33636 g
C Cl 102.5 mmol/l 2.068279 mmol/l   
D Weight 243 g 32.84644 g
D Cl 101.6 mmol/l  4.695151 mmol/l
Table 3. Statistical significance of mean values difference for groups (DG) after statistical standard t test application. 
DG Variable Difference  p-value   
Α-Β Weight -19 g 0.2423
Α-Β Cl 0.5 mmol/l 0.6262
Α-C Weight 0.2 g 0.9900
Α-C Cl 0.9 mmol/l 0.3783
Α-D Weight 0 g 1.0000
Α-D Cl 1.8 mmol/l 0.3203
Β-C Weight 19.2 g 0.2598
Β-C Cl 0.4 mmol/l 0.7109    
Β-D Weight 19 g 0.1011
Β-D Cl 1.3 mmol/l 0.4987
C-D Weight -0.2 g 0.9883
C-D Cl 0.9 mmol/l  0.5692
      
                                                                                                                                                 
Table 4. The decreasing influence of erythropoietin in connection with reperfusion time.
                                                             p-values
Decrease 95% c. in. Reperfusion time      t-test Glm
0.9 mmol/l -2.867103 mmol/l - 1.067103 mmol/l             1h 0.3783               0.3492      
1.1 mmol/l -2.944603 mmol/l - 0.7446032 mmol/l           1.5h 0.2922               0.2348     
1.3 mmol/l -4.668034 mmol/l - 2.068034 mmol/l              2h 0.4987               0.4280           
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0.7 mmol/l -2.565532 mmol/l - 1.165532 mmol/l  reperfusion time        0.4392                0.4522
0.7636364 mmol/l  -1.869013 mmol/l - 0.3417403 mmol/l  interaction  - 0.1701
Table 5. The (%) decreasing influence of erythropoietin in connection with reperfusion time.                                                                                                                      
Decrease  +SD Reperfusion time  p-values  
0.87% +0.97% 1h 0.3637      
1.07% +0.91% 1.5h 0.2635     
1.27%  +1.68% 2h 0.4633           
0.68% +0.92% reperfusion time 0.4457
0.74% +0.54%  interaction 0.1701
DISCUSSION
Frequently, the change in Cl levels is asso-
ciated with relevant changes in sodium lev-
els. Sodium is the main electrolyte found 
in extracellular fluid and is involved in flu-
id balance and blood pressure control. All 
known higher life forms require a subtle 
and complex electrolyte balance between 
the intracellular and extracellular environ-
ment. In particular, the maintenance of 
precise osmotic gradients of electrolytes is 
of major importance. Such gradients affect 
and regulate the hydration of the body as 
well as blood pH. However, when sodium 
chloride (NaCl) is placed in serum, the 
salt dissolves into its component ions, due 
to thermodynamic interactions between 
serum and solute molecules according to 
dissociation reaction salvation: NaCl(s) → 
Na+(aq) + Cl−(aq)
Thus, the vast content of chloride in serum 
is as independent chloride ion Cl-(aq) and 
not as salt. For this reason, an individual 
and autonomous consideration of chloride 
regardless of sodium conjugate should be 
considered complete. Unpleasantly, there 
are not described situations concerning 
whether hypoxia can influence only the 
Cl levels in bibliography. On the contrary, 
there are a lot of cases reporting how the 
Cl levels fluctuations affect the function 
of various organs. Such examples are de-
scribed herein. Nevertheless, isolated Cl 
administration is impossible. It is meant 
that, Cl is administered conjugated with 
another ion or factor possibly influenc-
ing the Cl levels. Le LL et al. achieved (3) 
brain ischemia-reperfusion (IR) injury 
three weeks after ischemic preconditioning 
(IPC) in rats. 2,3,5-triphenyltetrazolium 
Cl staining showed that IPC significantly 
reduced brain infarct area and improved 
neurological function of future cerebral in-
jury. Rehni AK et al. measured cerebral in-
farct size by using triphenyltetrazolium Cl 
staining and found (4) beneficial effects of 
IPC on global cerebral IR-induced cerebral 
injury and behavioral deficits in mice. Hin-
kel R et al. determined segmental endocar-
dial shortening in coronary IR infarct zone 
and infarct size by triphenyl tetrazolium Cl 
viability and found the 24 hours survival 
of neonatal pigs cardiomyocytes increased 
(5) by 2.8-fold than control ones after em-
bryonic endothelial progenitor cells (5x106 
cells) application in vivo. Murlasits Z et al. 
determined infarct area by a histological 
[triphenyltetrazolium Cl (TTC)] method, 
resulting in (6) cardioprotection as evi-
denced by reduced infarct size (P<0.05) in 
exercise-trained male Sprague-Dawley rats 
followed by bouts (70% of O2max). Mozaf-
fari MS et al. found markedly worsened (7) 
contractile function following IR injury 
but infarct size reduced by 5 weeks salt 
(1% NaCl solution) regimen administra-
tion than control groups in male rats. Birn-
baum Y et al. assessed (8) infarct size by 
triphenyltetrazolium Cl in male Sprague-
Dawley both case and placebo rats groups 
(p = 0.503). Kadambi A et al. observed 
(9) elevated xanthine oxidase levels in rat 
muscles subjected to IR + 0.9% saline than 
non ischemic controls ones.
Also the majority of the following exam-
ples concern the influence of Cl levels 
fluctuation on Epo levels. The minority 
of examples concern the influence of Epo 
fluctuation on the Cl levels. Tringali G et 
al. found (10) that brain hypoxia-ischemia 
increases the Epo levels which inhibited 
the 56 mM KCl-induced CRH release 
than control ones. Freudenthaler S et al. 
found none concomitant alteration of Epo 
concentrations affected after high (HS), 
normal (NS) or low (LS) salt diet admin-
istration (P = 0.54) in (11) volunteer ones. 
Freudenthaler SM et al. demonstrated (12) 
no significant differences of AUC (Epo(0-
48 h)) although Epo concentration in 
plasma was increased up to 290% of the 
baseline level, treating human volunteers 
by a short-term 0.9% NaCl administration 




tion time and their interaction have non 
significant short-term decreasing effects 
on Cl levels. Perhaps, a longer study time 
or a greater Epo dose may reveal clearer 
and significant effects.  
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